Journal
NUCLEAR MEDICINE COMMUNICATIONS
Volume 44, Issue 10, Pages 834-842Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MNM.0000000000001736
Keywords
brain; dementia; epilepsy; neuroimaging; Parkinson disease; PET; quantification; SPECT
Ask authors/readers for more resources
This study evaluated the use of Brain SPECT and PET scans in the UK and explored drivers and barriers to using quantitative analysis through an online survey. The results showed variations across the UK, with high availability of DaTscan imaging and quantification and lower availability of other SPECT and PET scans.
ObjectivesWith disease-modifying therapies in development for neurological disorders, quantitative brain imaging techniques become increasingly relevant for objective early diagnosis and assessment of response to treatment. The aim of this study was to evaluate the use of Brain SPECT and PET scans in the UK and explore drivers and barriers to using quantitative analysis through an online survey.MethodsA web-based survey with 27 questions was used to capture a snapshot of brain imaging in the UK. The survey included multiple-choice questions assessing the availability and use of quantification for DaTscan, Perfusion SPECT, FDG PET and Amyloid PET. The survey results were reviewed and interpreted by a panel of imaging experts.ResultsForty-six unique responses were collected and analysed, with 84% of responses from brain imaging sites. Within these sites, 88% perform DaTscan, 50% Perfusion SPECT, 48% FDG PET, and 33% Amyloid PET, while a few sites use other PET tracers. Quantitative Brain analysis is used in 86% of sites performing DaTscans, 40% for Perfusion SPECT, 63% for FDG PET and 42% for Amyloid PET. Commercial tools are used more frequently than in-house software.ConclusionThe survey showed variations across the UK, with high availability of DaTscan imaging and quantification and lower availability of other SPECT and PET scans. The main drivers for quantification were improved reporting confidence and diagnostic accuracy, while the main barriers were a perception of a need for an appropriate database of healthy controls and a lack of training, time, and software availability.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available